Double-Blind Rituximab

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	4

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03844061 (ClinicalTrials.gov)	July 29, 2019	31/1/2019	Belimumab and RituximabCombination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis ...	A Randomized, Double-Blind, Placebo-Controlled Study of Belimumab and RituximabCombination Therapy f ...	Systemic Sclerosis	Drug: Belimumab;Drug: Rituximab;Other: Placebo Subcutaneous Injection;Other: Placebo Infusion;Drug: ...	Hospital for Special Surgery, New York	GlaxoSmithKline	Recruiting	18 Years	80 Years	All	30	Phase 2	United States
2	NCT04274257 (ClinicalTrials.gov)	December 4, 2017	13/2/2020	A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis	Double-Blind, Parallel-group Comparison, Investigators Initiated Phase II Clinical Trial of IDEC-C2B ...	Scleroderma, Systemic;Skin Sclerosis;Lung Fibrosis;Autoimmune Diseases;Collagen Diseases	Drug: Double-Blind Placebo;Drug: Double-Blind Rituximab	Tokyo University	Japan Agency for Medical Research and Development;Zenyaku Kogyo Co., Ltd.	Completed	20 Years	80 Years	All	56	Phase 2/Phase 3	Japan
3	EUCTR2012-004955-35-IT (EUCTR)	29/07/2013	30/05/2013	A single-center randomized double-blindplacebo-controlled trial Treatment of Systemic Sclerosis with ...	A single-center randomized double-blindplacebo-controlled trial Treatment of Systemic Sclerosis with ...	SYSTEMIC SCLEROSIS MedDRA version: 16.0;Level: PT;Classification code 10042953;Term: Systemic sclero ...	Trade Name: Mabthera	POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
4	NCT01086540 (ClinicalTrials.gov)	June 24, 2011	11/3/2010	Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)	A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody ...	Systemic Sclerosis-Associated PAH	Biological: Rituximab;Other: Placebo;Diagnostic Test: CMRI;Drug: prednisone;Drug: methylprednisolone ...	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Completed	18 Years	75 Years	All	57	Phase 2	United States

First Previous1Next Last